
Prostaglandin E2 (PGE2) signals through E-type prostanoid (EP) receptors, among which EP4 receptors couple to Gαs protein to induce cAMP formation and also to Gαi protein to induce phosphorylation of extracellular signal-regulated kinases (ERKs). Although PGE2 acts as a pro-inflammatory mediator during the early phase of inflammation, PGE2-activated EP4 receptor signaling has also been implicated in the resolution phase. Resolvin E-series (RvEs), including RvE1, RvE2, and RvE3, are specialized pro-resolving mediators that promote the resolution of inflammation. We previously reported that RvE1 and RvE2, but not RvE3, suppressed cyclooxygenase-2 expression and PGE2 production. Because our previous studies addressed PGE2 production, we herein examined their impact on PGE2-stimulated EP4 receptor-mediated signaling. RvE3, but not RvE1 or RvE2, enhanced PGE2-stimulated cAMP formation, accompanied by increased EP4 receptor-mediated Gαs protein activation. In contrast, RvE3 did not increase Gαi protein activation or phosphorylation of ERKs. Therefore, RvE3 appears to selectively enhance EP4 receptor/Gαs protein-mediated cAMP signaling. Taken together with our previous findings, the present results suggest that RvE3 regulates PGE2-related responses through a mechanism that is distinct from those of RvE1 and RvE2, which may collectively contribute to the resolution of inflammation.
Fucoidan, a marine polysaccharide, has demonstrated potential in treating cardiovascular diseases, including coronary artery disease (CAD). CAD treatment includes lowering blood coagulation, blood fat levels, and having heart-protective activity. This study aimed to evaluate the potential of fucoidan compounds isolated from brown algae (Sargassum polycystum C. Agardh) on anticoagulant effects through measurements of PT, APTT, and TT, as well as lipid profile, body weight, heart and aortic mass index, LDH, and CK-MB, as well as in Wistar rats (Rattus norvegicus). A total of 36 animals were divided into six groups. Group I received a standard diet without treatment; Group II received 0.5% CMC; Group III was treated with simvastatin at 20 mg/kg BW; and Groups IV, V, and VI received fucoidan at doses of 30 mg/200 g BW, 40 mg/200 g BW, and 50 mg/200 g BW, respectively. Statistical analysis of the lipid profile showed that all fucoidan doses significantly reduced total cholesterol and triglyceride levels, although HDL levels were not increased. Organ weight analysis revealed a significant reduction (p < 0.05) in aortic weight in all treated groups, while no significant changes were observed in body or heart weight. Seven days of fucoidan administration also significantly reduced CK-MB and LDH serum levels (p < 0.05). In conclusion, fucoidan compounds Sargassum polycystum C. Agardh at all tested doses show potential in the treatment of CAD by lowering total cholesterol and triglyceride levels, reducing aortic weight, prolonging coagulation times (PT, APTT, and TT), and decreasing CK-MB and LDH levels.
A complex metabolic condition i.e. obesity is linked to a number of health issues, such as Diabetes, metabolic dysfunctions and cardiovascular disorders etc. Body weight control has often been misunderstood, with eating habits and exercise levels portrayed as personal preferences, usually associated with self-control or lack thereof. However, obesity is more than just a matter of choice in food habits, it is characterized by an excess of macrophage infiltration in adipose tissue, adipocyte hypertrophy, and disruptions in normal metabolic functions. An important contributing factor to the rising prevalence of obesity is disturbed eating patterns, frequently driven by cravings rather than actual hunger. Hypothalamus, particularly the arcuate nucleus plays an important role in regulating hunger and energy homeostasis in the body. The arcuate nucleus regulates appetite through two primary pathways: the orexigenic (appetite-stimulating) and anorexigenic (appetite-suppressing) systems. Remarkably, the endocannabinoid system (ECS) plays a key role in modulating both homeostatic and non-homeostatic aspects of food intake through its cannabinoid receptor 1 and 2 by interacting with various hypothalamic regions controlling hunger feeding patterns of hedonic and reward feeding. This review focuses on the role of ECS control on hypothalamic regulation of appetite, & hedonic or reward feeding patterns. A deeper understanding of these pathways is essential for addressing the growing prevalence of obesity and its associated health risks.
Caloric restriction (CR) is among the most effective non-genetic strategies to extend lifespan and delay age-related metabolic decline. Yet, the molecular mediators linking CR to hepatic protection remain incompletely understood. Here, we performed age-stratified targeted oxylipin (lipid mediator) profiling of livers from ad libitum (AL) and CR mice across adulthood and aging. In AL-fed mice, similar to 9 months emerged as an inflection point where oxylipin networks shifted toward a pro-inflammatory state, marked by transient elevations in PGE(2), 11-keto-TXB2, 20-HETE, and 5-oxo-ETE, with concomitant loss of pro-resolving/hydroxy-dihydroxylated mediators. Later life was characterized by depletion of CYP-derived epoxides and accumulation of soluble epoxide hydrolase (sEH)-generated diols, indicating impaired epoxide-to-diol coupling and resolution capacity. Lifelong CR dynamically reprogrammed these trajectories, blunting mid-life inflammatory surges, preserving EPA-derived epoxy-fatty acids (eg., EpETEs), and inducing the redox enzyme CYB5R3, which may sustain CYP epoxygenase activity (and epoxide output) despite reduced enzyme abundance. These oxylipin changes coincided with reduced hepatic lipid accumulation and a more favorable systemic metabolic profile in CR mice. Collectively, these findings identify age-and diet-associated remodeling of the hepatic COX/LOX/CYP oxylipin network, particularly the epoxide-diol profile, and nominate CYB5R3-associated redox regulation as a hypothesis for future mechanistic investigation.